Effects of RNA interference targeting transforming growth factor-beta 1 on immune hepatic fibrosis induced by Concanavalin A in mice

Hepatobiliary and Pancreatic Diseases International

Volumn 8, Issue 3, 2009, Pages 300-308

  Xu, Wei ^a   Wang, Lu Wen ^a   Shi, Jin Zhi ^a   Gong, Zuo Jiong ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

Liver fibrosis; Small interference RNA; Transforming growth factor beta 1

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CONCANAVALIN A; HYDROXYPROLINE; SHORT HAIRPIN RNA; SMAD3 PROTEIN; SMAD7 PROTEIN; SMALL INTERFERING RNA; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EXPRESSION VECTOR; FIBROGENESIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECOMBINANT PLASMID; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE;

ACTINS; ANIMALS; CONCANAVALIN A; DOWN-REGULATION; HYDROXYPROLINE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED STRAINS; PLASMIDS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

EID: 67549099372     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 2001;21:437-451. (Pubitemid 32923771)
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005;115:209-218. (Pubitemid 40385459)
3. Bataller R, Paik YH, Lindquist JN, Lemasters JJ, Brenner DA. Hepatitis C virus core and nonstructural proteins induce fibrogenic effects in hepatic stellate cells. Gastroenterology 2004;126:529-540. (Pubitemid 38182310)
4. Ramadori G, Saile B. Portal tract fibrogenesis in the liver. Lab Invest 2004;84:153-159. (Pubitemid 41656496)
5. Wanless IR, Shiota K. The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis. Semin Liver Dis 2004;24:99-106. (Pubitemid 38496052)
6. Saxena NK, Titus MA, Ding X, Floyd J, Srinivasan S, Sitaraman SV, et al. Leptin as a novel profibrogenic cytokine in hepatic stellate cells: mitogenesis and inhibition of apoptosis mediated by extracellular regulated kinase (Erk) and Akt phosphorylation. FASEB J 2004;18:1612-1614. (Pubitemid 39561650)
7. Bridle KR, Crawford DH, Ramm GA. Identification and characterization of the hepatic stellate cell transferrin receptor. Am J Pathol 2003;162:1661-1667. (Pubitemid 36512849)
8. Myung SJ, Yoon JH, Gwak GY, Kim W, Yang JI, Lee SH, et al. Bile acid-mediated thrombospondin-1 induction in hepatocytes leads to transforming growth factor-beta-dependent hepatic stellate cell activation. Biochem Biophys Res Commun 2007;353:1091-1096. (Pubitemid 46080410)
9. Breitkopf K, Haas S, Wiercinska E, Singer MV, Dooley S. Anti-TGF-beta strategies for the treatment of chronic liver disease. Alcohol Clin Exp Res 2005;29:121S-131S. (Pubitemid 43194338)
10. Li MO, Flavell RA. TGF-beta: a master of all T cell trades. Cell 2008;134:392-404.
11. Wynn TA. Fibrotic disease and the T(H)1/T(H) 2 paradigm. Nat Rev Immunol 2004;4:583-594.
12. Gauldie J, Bonniaud P, Sime P, Ask K, Kolb M. TGF-beta, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-664.
13. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets. J Cell Mol Med 2006;10:76-99. (Pubitemid 44874293)
14. Vickers TA, Koo S, Bennett CF, Crooke ST, Dean NM, Baker BF. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003;278:7108-7118. (Pubitemid 36800708)
15. Holen T, Amarzguioui M, Wiiger MT, Babaie E, Prydz H. Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor. Nucleic Acids Res 2002;30:1757-1766. (Pubitemid 34679753)
16. Tuschl T. Expanding small RNA interference. Nat Biotechnol 2002;20:446-448. (Pubitemid 34495927)
17. Inoue A, Sawata SY, Taira K. Molecular design and delivery of siRNA. J Drug Target 2006;14:448-455. (Pubitemid 44592896)
18. Song E, Lee SK, Wang J, Ince N, Ouyang N, Min J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med 2003;9:347-351.
19. Zhang G, Budker V, Wolff JA. High levels of foreign gene expression in hepatocytes after tail vein injections of naked plasmid DNA. Hum Gene Ther 1999;10:1735-1737. (Pubitemid 29328217)
20. Liu F, Song Y, Liu D. Hydrodynamics-based transfection in animals by systemic administration of plasmid DNA. Gene Ther 1999;6:1258-1266. (Pubitemid 29359019)
21. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA. A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 1994;20:349-355. (Pubitemid 24233360)
22. Chen MH, Chen JC, Tsai CC, Wang WC, Chang DC, Tu DG, et al. The role of TGF-beta 1 and cytokines in the modulation of liver fibrosis by Sho-saiko-to in rat's bile duct ligated model. J Ethnopharmacol 2005;97:7-13. (Pubitemid 40094520)
23. Moreira RK. Hepatic stellate cells and liver fibrosis. Arch Pathol Lab Med 2007;131:1728-1734. (Pubitemid 350077474)
24. Lu Y, Wu LQ, Li CS, Wang SG, Han B. Expression of transforming growth factors in hepatocellular carcinoma and its relations with clinicopathological parameters and prognosis. Hepatobiliary Pancreat Dis Int 2008;7:174-178.
25. Lebensztejn DM, Sobaniec-Lotowska M, Kaczmarski M, Werpachowska I, Sienkiewicz J. Serum concentration of transforming growth factor (TGF)-beta 1 does not predict advanced liver fibrosis in children with chronic hepatitis B. Hepatogastroenterology 2004;51:229-233. (Pubitemid 38283099)
26. Dong ZZ, Yao DF, Yao M, Qiu LW, Zong L, Wu W, et al. Clinical impact of plasma TGF-beta1 and circulating TGF-beta1 mRNA in diagnosis of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int 2008;7:288-295. (Pubitemid 351895389)
27. Kisseleva T, Brenner DA. Role of hepatic stellate cells in fibrogenesis and the reversal of fibrosis. J Gastroenterol Hepatol 2007;22:S73-78. (Pubitemid 46848997)
28. Cutroneo KR. TGF-beta-induced fibrosis and SMAD signaling: oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring. Wound Repair Regen 2007;15:S54-60. (Pubitemid 47301675)
29. Clarke DC, Liu X. Decoding the quantitative nature of TGF-beta/Smad signaling. Trends Cell Biol 2008;18:430-442.
30. Breitkopf K, Godoy P, Ciuclan L, Singer MV, Dooley S. TGF-beta/Smad signaling in the injured liver. Z Gastroenterol 2006;44:57-66.
31. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003;425:577-584. (Pubitemid 37280136)
32. Lewis DL, Wolff JA. Delivery of siRNA and siRNA expression constructs to adult mammals by hydrodynamic intravascular injection. Methods Enzymol 2005;392:336-350. (Pubitemid 40092524)
33. Maruyama H, Higuchi N, Nishikawa Y, Kameda S, Iino N, Kazama JJ, et al. High-level expression of naked DNA delivered to rat liver via tail vein injection. J Gene Med 2002;4:333-341. (Pubitemid 40268369)
34. Giladi H, Ketzinel-Gilad M, Rivkin L, Felig Y, Nussbaum O, Galun E. Small interfering RNA inhibits hepatitis B virus replication in mice. Mol Ther 2003;8:769-776. (Pubitemid 37527452)
35. Zender L, Hutker S, Liedtke C, Tillmann HL, Zender S, Mundt B, et al. Caspase 8 small interfering RNA prevents acute liver failure in mice. Proc Natl Acad Sci U S A 2003;100:7797-7802.